Who
Bruce L. A. Carter
Director
Company insider
Files Form 4 as: Director, Enanta Pharmaceuticals; Director, Mirati Therapeutics; Director, Xencor; Director, Regulus Therapeutics; Director, Qlt Inc/bc; CEO & Chairman of the Board, Zymogenetics; Director, Renovis.
In numbers
- Trades disclosed
- 155
- Buys
- 3
- Sells
- 24
- Bought
- $340K
- Sold
- $8.6M
- Companies
- 7
- Companies where not an officer
- 6
- First trade
- 5 Jan 2006
- Last trade
- 11 Mar 2026
- Last filed
- 13 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Mar 2026filed 13 Mar 2026 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 11 Mar 2026filed 13 Mar 2026 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 13 Mar 2025filed 14 Mar 2025 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,700 at $0.00 | filing |
| 6 Mar 2024filed 8 Mar 2024 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,700 at $0.00 | filing |
| 23 Jan 2024filed 23 Jan 2024 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 23 Jan 2024filed 23 Jan 2024 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code D | —7,520 | filing |
| 23 Jan 2024filed 23 Jan 2024 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code D | —11,000 | filing |
| 23 Jan 2024filed 23 Jan 2024 | Mirati Therapeutics | SEC FORM 4 Code D | —6,021 | filing |
| 23 Jan 2024filed 23 Jan 2024 | Mirati Therapeutics | SEC FORM 4 Code D | —4,444 | filing |
| 23 Jan 2024filed 23 Jan 2024 | Mirati Therapeutics | SEC FORM 4 Code D | —6,808 | filing |
| 29 Dec 2023filed 3 Jan 2024 | Mirati Therapeutics | SEC FORM 4 Code A | $400K6,808 at $58.75 | filing |
| 2 Mar 2023filed 6 Mar 2023 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,800 at $0.00 | filing |
| 20 Jan 2023filed 24 Jan 2023 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code A | —7,520 at $0.00 | filing |
| 20 Jan 2023filed 24 Jan 2023 | Mirati Therapeutics | SEC FORM 4 Code A | —4,444 at $0.00 | filing |
| 12 Aug 2022filed 16 Aug 2022 | Mirati Therapeuticsoption or derivative | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 12 Aug 2022filed 16 Aug 2022 | Mirati Therapeutics | SEC FORM 4 Code M | $270K10,000 at $27.00 | filing |
| 12 Aug 2022filed 16 Aug 2022 | Mirati Therapeutics | SEC FORM 4 Sold | $434K5,107 at $85.04 | filing |
| 12 Aug 2022filed 16 Aug 2022 | Mirati Therapeutics | SEC FORM 4 Sold | $421K4,893 at $85.96 | filing |
| 21 Mar 2022filed 22 Mar 2022 | ENTA Enanta Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —6,000 at $0.00 | filing |
| 21 Mar 2022filed 22 Mar 2022 | ENTA Enanta PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $153K6,000 at $25.58 | filing |
News
Comparing Amphastar Pharmaceuticals (NASDAQ:AMPH) & Enanta Pharmaceuticals (NASDAQ:ENTA)ENTA · tickerreport.com · 13 Oct 2026Contrasting Enanta Pharmaceuticals (NASDAQ:ENTA) and Scilex (NASDAQ:SCLX)ENTA · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Bruce L. A. Carter; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.